BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9054837)

  • 1. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.
    Hornig B; Kohler C; Drexler H
    Circulation; 1997 Mar; 95(5):1115-8. PubMed ID: 9054837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure.
    Hornig B; Arakawa N; Haussmann D; Drexler H
    Circulation; 1998 Dec 22-29; 98(25):2842-8. PubMed ID: 9860785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans.
    Haefeli WE; Linder L; Lüscher TF
    Hypertension; 1997 Oct; 30(4):912-7. PubMed ID: 9336392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism.
    Hornig B; Kohler C; Schlink D; Tatge H; Drexler H
    Hypertension; 2003 May; 41(5):1092-5. PubMed ID: 12654707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction.
    Benacerraf S; Carville C; Adnot S; Montagne O; Sediame S; Belhassen L; Dubois-Randé JL
    J Cardiovasc Pharmacol; 1999 Sep; 34(3):368-73. PubMed ID: 10470994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
    Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
    J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium.
    Hecker M; Bara AT; Busse R
    Eur Heart J; 1993 Nov; 14 Suppl I():161-3. PubMed ID: 8293768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level.
    Hecker M; Pörsti I; Bara AT; Busse R
    Br J Pharmacol; 1994 Jan; 111(1):238-44. PubMed ID: 8012702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade.
    Tom B; de Vries R; Saxena PR; Danser AH
    Hypertension; 2001 Jul; 38(1):95-9. PubMed ID: 11463767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men.
    Squire IB; O'Kane KP; Anderson N; Reid JL
    Hypertension; 2000 Jul; 36(1):132-6. PubMed ID: 10904025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism.
    Zanzinger J; Zheng X; Bassenge E
    Cardiovasc Res; 1994 Feb; 28(2):209-14. PubMed ID: 8143302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats.
    Benetos A; Levy BI; Lacolley P; Taillard F; Duriez M; Safar ME
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3196-201. PubMed ID: 9409311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
    Gainer JV; Morrow JD; Loveland A; King DJ; Brown NJ
    N Engl J Med; 1998 Oct; 339(18):1285-92. PubMed ID: 9791144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
    Hornig B; Arakawa N; Drexler H
    Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.
    Cockcroft JR; Chowienczyk PJ; Brett SE; Bender N; Ritter JM
    Br J Clin Pharmacol; 1994 Oct; 38(4):317-21. PubMed ID: 7833220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
    Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
    Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin.
    Prasad A; Husain S; Quyyumi AA
    J Am Coll Cardiol; 1999 Mar; 33(3):796-804. PubMed ID: 10080484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic response to bradykinin in isolated porcine iliac arteries is mediated by bradykinin B1 and B2 receptors.
    Persson K; Andersson RG
    J Cardiovasc Pharmacol; 1998 Feb; 31(2):306-13. PubMed ID: 9475274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
    Stauss HM; Zhu YC; Redlich T; Adamiak D; Mott A; Kregel KC; Unger T
    J Cardiovasc Risk; 1994 Oct; 1(3):255-62. PubMed ID: 7621306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels.
    Endlich K; Steinhausen M
    J Hypertens; 1997 Jun; 15(6):633-41. PubMed ID: 9218183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.